# VAccination in Early and ADvanced Prostate caNCEr

> **NCT03815942** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Oxford** · enrollment: 23 (actual)

## Conditions studied

- Intermediate Risk Prostate Cancer
- Castration-resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** ChAdOx1-MVA 5T4 vaccine
- **DRUG:** Nivolumab Infusion [Opdivo]

## Key facts

- **NCT ID:** NCT03815942
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-10
- **Primary completion:** 2020-06-24
- **Final completion:** 2020-06-24
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** COVID stopped all trials - and ADVANCE could not restart again after the pandemic
- **Last updated:** 2025-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03815942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03815942, "VAccination in Early and ADvanced Prostate caNCEr". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03815942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*